IL308335A - Combination therapies - Google Patents
Combination therapiesInfo
- Publication number
- IL308335A IL308335A IL308335A IL30833523A IL308335A IL 308335 A IL308335 A IL 308335A IL 308335 A IL308335 A IL 308335A IL 30833523 A IL30833523 A IL 30833523A IL 308335 A IL308335 A IL 308335A
- Authority
- IL
- Israel
- Prior art keywords
- combination therapies
- therapies
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021093036 | 2021-05-11 | ||
| CN2021100523 | 2021-06-17 | ||
| CN2022086004 | 2022-04-11 | ||
| PCT/CN2022/091679 WO2022237720A1 (en) | 2021-05-11 | 2022-05-09 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308335A true IL308335A (en) | 2024-01-01 |
Family
ID=81753154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308335A IL308335A (en) | 2021-05-11 | 2022-05-09 | Combination therapies |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4337216A1 (en) |
| JP (1) | JP2024518497A (en) |
| KR (1) | KR20240006631A (en) |
| CN (1) | CN117460513A (en) |
| AU (1) | AU2022274071A1 (en) |
| CA (1) | CA3215313A1 (en) |
| CL (1) | CL2023003239A1 (en) |
| CO (1) | CO2023014322A2 (en) |
| DO (1) | DOP2023000246A (en) |
| IL (1) | IL308335A (en) |
| MX (1) | MX2023013410A (en) |
| PE (1) | PE20240593A1 (en) |
| TW (1) | TW202308643A (en) |
| UY (1) | UY39761A (en) |
| WO (1) | WO2022237720A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114664A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3233857T3 (en) | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Solid state forms of fused heteroaromatic pyrrolidinones |
| US20190010167A1 (en) * | 2015-12-22 | 2019-01-10 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| KR20220123727A (en) * | 2016-06-10 | 2022-09-08 | 비타이 파마슈티컬즈, 엘엘씨 | Inhibitors of the menin-mll interaction |
| TW202104207A (en) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | Dihydroorotate dehydrogenase inhibitors |
| CR20220346A (en) | 2019-12-19 | 2022-10-26 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
-
2022
- 2022-05-09 MX MX2023013410A patent/MX2023013410A/en unknown
- 2022-05-09 WO PCT/CN2022/091679 patent/WO2022237720A1/en active Application Filing
- 2022-05-09 JP JP2023569789A patent/JP2024518497A/en active Pending
- 2022-05-09 AU AU2022274071A patent/AU2022274071A1/en active Pending
- 2022-05-09 CN CN202280034525.XA patent/CN117460513A/en active Pending
- 2022-05-09 EP EP22725158.4A patent/EP4337216A1/en active Pending
- 2022-05-09 IL IL308335A patent/IL308335A/en unknown
- 2022-05-09 PE PE2023003030A patent/PE20240593A1/en unknown
- 2022-05-09 CA CA3215313A patent/CA3215313A1/en active Pending
- 2022-05-09 KR KR1020237042402A patent/KR20240006631A/en unknown
- 2022-05-10 TW TW111117441A patent/TW202308643A/en unknown
- 2022-05-10 UY UY0001039761A patent/UY39761A/en unknown
-
2023
- 2023-10-25 CO CONC2023/0014322A patent/CO2023014322A2/en unknown
- 2023-10-31 CL CL2023003239A patent/CL2023003239A1/en unknown
- 2023-11-08 DO DO2023000246A patent/DOP2023000246A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240593A1 (en) | 2024-03-21 |
| CO2023014322A2 (en) | 2023-11-20 |
| CL2023003239A1 (en) | 2024-06-07 |
| DOP2023000246A (en) | 2024-04-30 |
| JP2024518497A (en) | 2024-05-01 |
| TW202308643A (en) | 2023-03-01 |
| KR20240006631A (en) | 2024-01-15 |
| CN117460513A (en) | 2024-01-26 |
| CA3215313A1 (en) | 2022-11-17 |
| WO2022237720A1 (en) | 2022-11-17 |
| UY39761A (en) | 2022-11-30 |
| EP4337216A1 (en) | 2024-03-20 |
| AU2022274071A1 (en) | 2024-01-04 |
| MX2023013410A (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102016B (en) | Combination therapies | |
| IL291659A (en) | Combination therapies | |
| EP3849535A4 (en) | Combination therapies | |
| ZA202212919B (en) | Transposition-based therapies | |
| EP3849536A4 (en) | Combination therapies | |
| EP3849534A4 (en) | Combination therapies | |
| ZA202102015B (en) | Combination therapies | |
| EP3860609A4 (en) | Combination therapies | |
| EP3930851A4 (en) | Combination therapies | |
| EP3849537A4 (en) | Combination therapies | |
| IL308333A (en) | Combination therapies | |
| IL308335A (en) | Combination therapies | |
| IL288237A (en) | Combination therapy | |
| IL310919A (en) | Combination therapies | |
| EP3844177A4 (en) | Combination therapies | |
| GB2580963B (en) | Cancer therapies | |
| GB202107907D0 (en) | Combination therapies | |
| IL287667A (en) | Combination therapies | |
| GB201916906D0 (en) | Combination therapies | |
| GB201906864D0 (en) | Combination therapy | |
| GB202316390D0 (en) | Combination therapies | |
| GB202305462D0 (en) | Combination therapies | |
| IL315041A (en) | Combination therapies | |
| GB202300007D0 (en) | Combination therapies | |
| ZA202200731B (en) | Combination therapy |